Vascular Pathways Gets FDA Nod for AccuCath Midline Catheter System

Vascular Pathways plans to launch its AccuCath 3.1" BC Midline Catheter in the U.S. next month, following the receipt of FDA 510(k) clearance. The device is meant to reach vasculature formerly thought too deep for traditional IV placement, President and CEO Bill Bold said Thursday.

Developed as an option for patients with challenged peripheral vasculature whose hospital stay lasts 29 days or less and who don’t require a central line, the system includes a 3.1-inch injectable catheter, blood control valve and patented AccuTip coiled Nitinol guidewire.

The product’s design is intended to increase first-time success, reduce complication rates, extend dwell times, increase patient satisfaction and lower overall provider costs, the Boca Raton, Fla., company said. — Jason Scott